DE69630969D1 - Verfahren zur hemmung des plasminogen-aktivator-inhibitors - Google Patents

Verfahren zur hemmung des plasminogen-aktivator-inhibitors

Info

Publication number
DE69630969D1
DE69630969D1 DE69630969T DE69630969T DE69630969D1 DE 69630969 D1 DE69630969 D1 DE 69630969D1 DE 69630969 T DE69630969 T DE 69630969T DE 69630969 T DE69630969 T DE 69630969T DE 69630969 D1 DE69630969 D1 DE 69630969D1
Authority
DE
Germany
Prior art keywords
inhibiting
plasminogen activator
activator inhibitor
inhibitor
plasminogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69630969T
Other languages
English (en)
Other versions
DE69630969T2 (de
Inventor
T Berg
W Grinnell
A Richardson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Application granted granted Critical
Publication of DE69630969D1 publication Critical patent/DE69630969D1/de
Publication of DE69630969T2 publication Critical patent/DE69630969T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/36—Antigestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
DE69630969T 1995-10-10 1996-10-07 Verfahren zur hemmung des plasminogen-aktivator-inhibitors Expired - Fee Related DE69630969T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US501595P 1995-10-10 1995-10-10
PCT/US1996/016059 WO1997013511A1 (en) 1995-10-10 1996-10-07 Methods of inhibiting plasminogen activator inhibitor 1

Publications (2)

Publication Number Publication Date
DE69630969D1 true DE69630969D1 (de) 2004-01-15
DE69630969T2 DE69630969T2 (de) 2004-10-21

Family

ID=21713702

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69630969T Expired - Fee Related DE69630969T2 (de) 1995-10-10 1996-10-07 Verfahren zur hemmung des plasminogen-aktivator-inhibitors

Country Status (20)

Country Link
US (1) US5731328A (de)
EP (1) EP0854715B1 (de)
JP (1) JPH11513665A (de)
KR (1) KR19990064099A (de)
CN (1) CN1199337A (de)
AR (1) AR003812A1 (de)
AT (1) ATE255414T1 (de)
AU (1) AU716655B2 (de)
CA (1) CA2234404A1 (de)
CO (1) CO4750819A1 (de)
CZ (1) CZ106098A3 (de)
DE (1) DE69630969T2 (de)
EA (1) EA001003B1 (de)
ES (1) ES2211981T3 (de)
HU (1) HUP9802348A3 (de)
NO (1) NO981578L (de)
NZ (1) NZ319948A (de)
PL (1) PL326294A1 (de)
WO (1) WO1997013511A1 (de)
ZA (1) ZA968444B (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2207141A1 (en) * 1996-07-15 1998-01-15 David Thompson Berg Benzothiophene compounds, and uses and formulations thereof
US5792798A (en) * 1996-07-29 1998-08-11 Eli Lilly And Company Method for inhibiting plasminogen activator inhibitor 1
US6025373A (en) * 1997-04-22 2000-02-15 Eli Lilly And Company Methods for reducing fibrinogen
EP1113007A1 (de) 1999-12-24 2001-07-04 Pfizer Inc. Tetrahydroisochinolin-Verbindungen zur Verwendung als Östrogen-Agonisten/-Antagonisten
US6586453B2 (en) 2000-04-03 2003-07-01 3-Dimensional Pharmaceuticals, Inc. Substituted thiazoles and the use thereof as inhibitors of plasminogen activator inhibitor-1
JPWO2006088011A1 (ja) * 2005-02-15 2008-07-03 学校法人東海大学 プラスミノーゲンアクチベーターインヒビター−１阻害剤
JP5242402B2 (ja) * 2005-10-11 2013-07-24 アマノ エンザイム ユーエスエー カンパニー，リミテッド Ｐａｉ−１の酵素阻害物質
CN101544138B (zh) * 2008-03-26 2012-05-23 山东新北洋信息技术股份有限公司 热转印打印机碳带回收装置

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
TW366342B (en) * 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
TW383306B (en) * 1992-12-22 2000-03-01 Lilly Co Eli New use of 2-phenyl-3-aroylbenzothiophenes in lowering serum cholesterol
CZ286365B6 (cs) * 1993-12-21 2000-03-15 Eli Lilly And Company Farmaceutický prostředek pro inhibici LDL oxidace a atherosklerosy

Also Published As

Publication number Publication date
EP0854715A1 (de) 1998-07-29
NO981578D0 (no) 1998-04-07
KR19990064099A (ko) 1999-07-26
CA2234404A1 (en) 1997-04-17
HUP9802348A3 (en) 1999-11-29
JPH11513665A (ja) 1999-11-24
US5731328A (en) 1998-03-24
EP0854715B1 (de) 2003-12-03
NO981578L (no) 1998-04-07
CN1199337A (zh) 1998-11-18
EA001003B1 (ru) 2000-08-28
WO1997013511A1 (en) 1997-04-17
ES2211981T3 (es) 2004-07-16
AR003812A1 (es) 1998-09-09
HUP9802348A2 (hu) 1999-08-30
CO4750819A1 (es) 1999-03-31
ATE255414T1 (de) 2003-12-15
DE69630969T2 (de) 2004-10-21
CZ106098A3 (cs) 1999-03-17
AU716655B2 (en) 2000-03-02
ZA968444B (en) 1998-04-07
NZ319948A (en) 2000-06-23
AU7259696A (en) 1997-04-30
EP0854715A4 (de) 2001-12-19
PL326294A1 (en) 1998-09-14
EA199800366A1 (ru) 1998-10-29

Similar Documents

Publication Publication Date Title
ID19198A (id) Inhibitor metaloprotease heterosiklik
ID18416A (id) Inhibitor metaloprotease diheterosiklik
DK0869966T3 (da) Prodrugs for thrombin-inhibitorer
DE69529936T2 (de) Verfahren zur Quantifizierung von spezifischen Verbindungen
FI952926A (fi) Menetelmät allergioiden hoitamiseksi tai ehkäisemiseksi
NO20006716D0 (no) Proteaseinhibitorer
DE69603277T2 (de) Verfahren zur plasma aktivierten wärmebehandlung von titannitrid
NO973657D0 (no) Trombin-inhibitorer
ATE239755T1 (de) Thrombin inhibitoren
DE69733883D1 (de) Verfahren zur zugabe von borverbindungen
DE731191T1 (de) Verfahren zur Verringerung der Korrosion
DE69526796D1 (de) Verfahren zur inhibierung von pflanzenkrankheiten
DE69433479D1 (de) Verfahren zum sanieren von abwassersystemen
DE69428364D1 (de) Verfahren zur brandbekämpfung
DE69838226D1 (de) Verfahren zur plasmabehandlung
DE69418318D1 (de) Verfahren zur krafterzeugung
DE69630969T2 (de) Verfahren zur hemmung des plasminogen-aktivator-inhibitors
DE69822526D1 (de) Verfahren zur Konservierung von wassergefüllten Materialien
PT863916E (pt) Tripeptidos de polifluoroalquil triptofano inibidores de trombina
DE69601540T2 (de) Verfahren zur oxychlorierung
ATE206392T1 (de) Verfahren zur alkylierug von gehinderten sulfonamiden
DE69609963T2 (de) Verfahren zur iodierung
DE59407937D1 (de) Verfahren zur Momentanfrequenz-Detektion
DE59604907D1 (de) Verfahren zur reduktion von nitroverbindungen
DE59404957D1 (de) Verfahren zur anregung von gasentladungen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee